We're focusing on high-value natural products with pharmaceutical potential
Natural Health Products
- $500-$5,000/kg compounds
- Rapidly growing market
Pharmaceutical Analogs
-
$5,000-$500,000+/kg compounds
-
Higher barriers to entry
The projects we currently have in our pipeline
NCT: Over-the-Counter
A rare natural product that activates the cell’s master metabolic control switch - finally available at scale. NCT opens a new category in metabolic wellness by addressing cellular energy efficiency rather than symptoms.
NCT: Pharma
A first-in-class approach to treating multiple metabolic diseases through a single upstream mechanism. Platform-enabled analogs of NCT unlock a previously inaccessible pharmaceutical pathway with clear acquisition relevance.
Non-intoxicating Cannabinoids
Novel, non-intoxicating molecules inspired by cannabinoid biology but unconstrained by traditional chemistry. The platform enables rapid exploration of new chemical space with multiple therapeutic and commercial pathways.
Santalene
A high-value fragrance molecule constrained by scarcity and unsustainable extraction. Cell-free production transforms santalene into a predictable, scalable ingredient while opening access to adjacent aromatic compounds.
From platform to commercial assets
Rapidly maturing potential candidate molecules
Three complementary commercialization pathways
Spin-Outs
Spin-outs are used when an opportunity supports the creation of a focused, standalone company with significant long-term value potential. In these cases, eXoZymes contributes proprietary technology, process know-how, and intellectual property, while the spin-out raises dedicated capital and builds an independent operating team.
This structure allows eXoZymes to retain meaningful equity exposure and upside, while limiting balance-sheet risk and preserving internal focus.
Joint-Ventures
Joint ventures are employed when strategic partners provide market access, infrastructure, or domain expertise that materially accelerates commercialization. In these structures, eXoZymes combines its platform and IP with a partner’s operational capabilities, allowing risk, capital requirements, and upside to be shared.
Joint ventures enable faster scaling and strong alignment between technology ownership and downstream execution.
Licensing
Licensing is used when partners are best positioned to commercialize an asset directly. eXoZymes licenses process technology, enzyme systems, or molecule-specific rights in exchange for upfront payments, milestones, royalties, or a combination thereof.
This pathway allows eXoZymes to monetize its platform at scale while remaining operationally lean and capital efficient.
A platform-of-platforms strategy
Want to be kept up to date?
We are excited to keep you updated with news tailored to your preferences. By subscribing to one or more streams, you'll receive information relevant to the areas you've selected. If you ever wish to update your preferences, you can do so at any time.